Ad hoc announcement pursuant to Art. 53 LR

Wolf-Rüdiger Daetz to leave Straumann


 
 

Basel, 9 July 2010 – Straumann, a global leader in implant and restorative dentistry and oral tissue regeneration, announced today that its Chief Financial Officer, Wolf-Rüdiger Daetz, has decided to leave the company at the end of September 2010 to pursue his career outside Straumann.

 

Mr Daetz, who joined Straumann from Siemens Building Technologies four months ago, will continue in his responsibilities until his departure. At that point, Beat Spalinger, President & CEO, will supervise Finance & Operations directly on an ad-interim basis until a successor to Mr Daetz is appointed. Beat Spalinger was formerly CFO of the Straumann Group and is supported by a highly professional Finance team.

 

Straumann is initiating a search for a successor to Mr Daetz and is confident that it will be able to announce the appointment in the near future.

 

 

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: investor.relations@straumann.com or corporate.communication@straumann.com

Homepage: www.straumann.com

 

 

Contacts:

 

Corporate Communication:

Mark Hill               

+41 (0)61 965 13 21

 

Thomas Konrad

+41 (0)61 965 15 46

 

Investor Relations:

Fabian Hildbrand

+41 (0)61 965 13 27

 

 

Disclaimer

This release contains certain “forward-looking statements”, which can be identified by the use of terminology such as “will”, “is appointed”, “is initiating”, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group’s products, the potential for the Group’s products to become obsolete, the Group’s ability to defend its intellectual property, the Group’s ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group’s ability to generate revenues and profitability, and the Group’s ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

 

 

About Straumann

Headquartered in Basel, Switzerland, the Straumann Group (SIX: STMN) is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

 

Upcoming reporting dates

19 August 2010 - Q2 sales and Half-year results 2010

28 October 2010 - Q3 and 9M sales 2010

15 February 2011 - Full-Year results 2010

 

Details on upcoming investor relations activities are published on www.straumann.com (Investor Relations > Calendar)

 

 

 

Downloads